Multiple sclerosis therapy: An update on recently finished trials

C. Kleinschnitz, S. G. Meuth, O. Stüve, B. Kieseier, H. Wiendl

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Six pharmacological agents are currently approved for the treatment of multiple sclerosis (MS).However, all established substances are only partially effective in reducing disease progression or relapse rates. In addition, they have potentially serious side effects. Thus, significant efforts are being made to develop new agents or to optimize current therapies. The latter includes modifications of dose, route of administration or the time point of treatment initiation. In this review, we provide an update on the most important clinical phase II/III trials on approved and novel immunotherapeutic strategies in MS reported during the last two years. Pharmacotherapies include agents that target chemoattraction, cell migration, chemotherapies, and antigen-based therapies.

Original languageEnglish (US)
Pages (from-to)1473-1490
Number of pages18
JournalJournal of Neurology
Volume254
Issue number11
DOIs
StatePublished - Nov 2007

Fingerprint

Multiple Sclerosis
Drug Therapy
Phase III Clinical Trials
Phase II Clinical Trials
Therapeutics
Cell Movement
Disease Progression
Pharmacology
Antigens
Recurrence

Keywords

  • Disease modifying drugs
  • Multiple sclerosis
  • Natalizumab
  • Therapy
  • Trials

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Multiple sclerosis therapy : An update on recently finished trials. / Kleinschnitz, C.; Meuth, S. G.; Stüve, O.; Kieseier, B.; Wiendl, H.

In: Journal of Neurology, Vol. 254, No. 11, 11.2007, p. 1473-1490.

Research output: Contribution to journalArticle

Kleinschnitz, C, Meuth, SG, Stüve, O, Kieseier, B & Wiendl, H 2007, 'Multiple sclerosis therapy: An update on recently finished trials', Journal of Neurology, vol. 254, no. 11, pp. 1473-1490. https://doi.org/10.1007/s00415-007-0684-7
Kleinschnitz, C. ; Meuth, S. G. ; Stüve, O. ; Kieseier, B. ; Wiendl, H. / Multiple sclerosis therapy : An update on recently finished trials. In: Journal of Neurology. 2007 ; Vol. 254, No. 11. pp. 1473-1490.
@article{973b08abf4db42a38af8e8dc94942f92,
title = "Multiple sclerosis therapy: An update on recently finished trials",
abstract = "Six pharmacological agents are currently approved for the treatment of multiple sclerosis (MS).However, all established substances are only partially effective in reducing disease progression or relapse rates. In addition, they have potentially serious side effects. Thus, significant efforts are being made to develop new agents or to optimize current therapies. The latter includes modifications of dose, route of administration or the time point of treatment initiation. In this review, we provide an update on the most important clinical phase II/III trials on approved and novel immunotherapeutic strategies in MS reported during the last two years. Pharmacotherapies include agents that target chemoattraction, cell migration, chemotherapies, and antigen-based therapies.",
keywords = "Disease modifying drugs, Multiple sclerosis, Natalizumab, Therapy, Trials",
author = "C. Kleinschnitz and Meuth, {S. G.} and O. St{\"u}ve and B. Kieseier and H. Wiendl",
year = "2007",
month = "11",
doi = "10.1007/s00415-007-0684-7",
language = "English (US)",
volume = "254",
pages = "1473--1490",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "11",

}

TY - JOUR

T1 - Multiple sclerosis therapy

T2 - An update on recently finished trials

AU - Kleinschnitz, C.

AU - Meuth, S. G.

AU - Stüve, O.

AU - Kieseier, B.

AU - Wiendl, H.

PY - 2007/11

Y1 - 2007/11

N2 - Six pharmacological agents are currently approved for the treatment of multiple sclerosis (MS).However, all established substances are only partially effective in reducing disease progression or relapse rates. In addition, they have potentially serious side effects. Thus, significant efforts are being made to develop new agents or to optimize current therapies. The latter includes modifications of dose, route of administration or the time point of treatment initiation. In this review, we provide an update on the most important clinical phase II/III trials on approved and novel immunotherapeutic strategies in MS reported during the last two years. Pharmacotherapies include agents that target chemoattraction, cell migration, chemotherapies, and antigen-based therapies.

AB - Six pharmacological agents are currently approved for the treatment of multiple sclerosis (MS).However, all established substances are only partially effective in reducing disease progression or relapse rates. In addition, they have potentially serious side effects. Thus, significant efforts are being made to develop new agents or to optimize current therapies. The latter includes modifications of dose, route of administration or the time point of treatment initiation. In this review, we provide an update on the most important clinical phase II/III trials on approved and novel immunotherapeutic strategies in MS reported during the last two years. Pharmacotherapies include agents that target chemoattraction, cell migration, chemotherapies, and antigen-based therapies.

KW - Disease modifying drugs

KW - Multiple sclerosis

KW - Natalizumab

KW - Therapy

KW - Trials

UR - http://www.scopus.com/inward/record.url?scp=36349022138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349022138&partnerID=8YFLogxK

U2 - 10.1007/s00415-007-0684-7

DO - 10.1007/s00415-007-0684-7

M3 - Article

C2 - 18004638

AN - SCOPUS:36349022138

VL - 254

SP - 1473

EP - 1490

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 11

ER -